← All drugs Report issue

k-134

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

0

Phase 2

1

Phase 3

0

Phase 4

0

Earliest trial started Nov 1, 2008 (NCT00783081)

Timeline

2000s

Jan 1, 2008
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Intermittent Claudication · Phase 2

Mechanism of action

Phosphodiesterase 3AINHIBITOR
PDE3A inhibitor
- cGMP-inhibited 3',5'-cyclic phosphodiesterase A (PDE3A) ↗
Phosphodiesterase 3INHIBITOR
Phosphodiesterase 3 inhibitor
- cGMP-inhibited 3',5'-cyclic phosphodiesterase A (PDE3A) ↗
- cGMP-inhibited 3',5'-cyclic phosphodiesterase B (PDE3B) ↗
- Phosphodiesterase 3A
- Phosphodiesterase 3B

Chemistry & pharmacology

Loading structure…

SMILES

O=C(NCCCOc1ccc2[nH]c(=O)ccc2c1)N(C1CC1)[C@@H]1CCCC[C@H]1O

Mol. weight: 399.49 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL284838 ↗

Also known as

k-134
k-134
k-134

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00783081	Phase 2	Nov 1, 2008	Kowa

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Kowa	For profit	1	1	1	2008

1 organizations

Page 1 / 1